Erratum

Please note the following correction to Lewis AP, Parry N, Peakman TC, Crowe JS. Rescue and expression of human immunoglobulin genes to generate functional human monoclonal antibodies. Hum Antibod Hybridomas 1992; 3:146. On page 148, column 2, third paragraph, line 7 should read: "library was plated and screened for human λ L chain," and on page 149, column 1, second paragraph, line 6 should read: "revealed positive λ chain cDNA clones. . ." In both lines, κ should be replaced by λ .

An international journal from Butterworth-Heinemann

MOLECULAR BIOTHERAPY

the international journal for the application of biologicals in clinical or veterinary practice

Robert K. Oldham, MD Biological Therapy Institute Franklin, TN USA

Associate Editors: Hiroshi Kobayashi, MD Hokkaido University School of Medicine Sapporo, Japan

R. T. D. Oliver, MD London Hospital Medical College London, England

Klaus Pfizenmaier, PhD Max-Planck-Gesellschaft Gottingen, FRG

Robert O. Dillman, MD Hoag Memorial Hospital . Presbyterian Newport Beach, CA, USA

ISSN: 0952-8172 North American Individuals, \$65.00 North American Institutions, \$160.00 Overseas Individuals, \$75.00 Overseas Institutions, \$200.00

Oversease prices include air mail. Prepayment is required in U.S. funds only.

Call for your sample issue today!

1-800-366-2665

Molecular Biotherapy serves as a forum to gather and present significant preclinical and clinical results in biotherapy to practicing physicians. Coverage includes impor-tant findings from international researchers in medical laboratories and biotechnology companies. The focus is on those biological approaches that appear to be translating rapidly from the laboratory to the clinic

The synthetic techniques of the genetic engineer have combined with new analytical methods and affinity separations based on poly and monoclonal antibodies which, with the new techniques of growing and exploiting animal cells at high (tissue-like) densities, have led to the discovery and small-scale production of a large number of biologicals. Biologicals of interest include:

- . monoclonal antibodies
- . immunoconjugates
- . interferons
- . interferon inducers . lymphokines and cytokines
- . effector cells
- . tumor vaccines
- . growth and maturation factors
- . hormones
- . receptor molecules . transforming proteins
- . adjuvants
- . suppressor factors
- . biological response modifiers
- . tumor antigens

Molecular Biotherapy publishes orginal manuscripts on experimental, clinical, and epidemiological aspects of therapeutic and prophylactic biologicals. (Papers which have been previously published or simultaneously submitted to another journal will mot be considered.)

Regular features include: rapid communications, review articles, book reviews, editorial commentary, correspondence, meeting reports, conference calendar, and industrial news.

Call for Papers

Original research papers and rapid communications are invited and should be submitted to the Editor, Dr. Robert K. Oldham, Biological Therapy Institute, Franklin, TN 37064 USA. Notes on manuscript preparation can be obtained from the publisher and manuscripts should be submitted to the Editor.

If this copy of Molecular Biotherapy is not your own, you can subcribe by calling 1-800-366-2665, or mail your request to the Journals Fulfillment Department at the address below!

SUTTERWORTH EINEMANN 80 Montvale Avenue, Stoneham MA 02180